EUVIMEDEUVIMED entdecken
Crossref

Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment

Valeria Capurro, Emanuela Pesce, Federico Cresta, Cristina Pastorino, Alice Mantero, Valeria Tomati, Valeria Daccò, Laura Claut, Benedetta Fabrizzi, Federico Zara, Carlo Castellani, Nicoletta Pedemonte

Journal of Cystic Fibrosis · 2026

DOI: 10.1016/j.jcf.2026.05.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026. Verfasst von Valeria Capurro und 11 weiteren Autor:innen. Beteiligte Einrichtung: UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Genova, Italy. Hauptthemen laut MEDLINE: Cystic Fibrosis, Quinolones, Cystic Fibrosis Transmembrane Conductance Regulator, Aminophenols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Ministero della Salute, Cystic Fibrosis Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The triple combination of Elexacaftor/Tezacaftor/Ivacaftor (ETI) has revolutionized cystic fibrosis (CF) treatment; however, a subset of patients with eligible genotypes remains unresponsive. We previously identified the L467F-F508del complex allele as a cause of therapeutic failure, conferring a severe processing defect that renders the CFTR protein refractory to ETI. METHODS: To address this unmet need, we evaluated the efficacy of the next-generation combination comprising Vanzacaftor/Tezacaftor (Vnz/Tez). We utilized primary human nasal epithelial (HNE) cells derived from six patients carrying the L467F-F508del complex allele and a minimal function mutation and monitored the clinical response of a patient treated with Vanzacaftor/Tezacaftor/Deutivacaftor (VTD) via compassionate use. Mechanistic validation was performed in CFBE41o- cells. RESULTS: In patient-derived HNE models, treatment with Vnz/Tez resulted in a consistent and significant rescue of CFTR activity, overcoming the block previously observed with ETI. Of note, we report a patient treated with VTD who experienced a partial improvement in pulmonary function (FEV1 +220 mL) and exercise tolerance and a decrease of sweat Chloride concentration from 100 to 87 mmol/L. In heterologous expression systems, Vnz/Tez, but not Elx/Tez, successfully restored the processing of the L467F-F508del mutant, promoting the formation of the mature, complex-glycosylated CFTR form. CONCLUSIONS: Our findings demonstrate that the Vanzacaftor/Tezacaftor combination possesses superior corrective potency capable of rescuing the severe trafficking defect of the L467F-F508del complex allele. This study identifies a promising therapeutic solution for patients currently orphaned by standard-of-care modulators and highlights the utility of integrating ex vivo screening with clinical monitoring in defining precision medicine strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisQuinolonesCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesIndolesHumansAllelesDrug CombinationsFemaleChloride Channel AgonistsDrug ResistanceMaleSpiro Compounds

Stichwörter der Autor:innen

Chloride secretionCorrectorsModulatorsNasal epithelial cellsNon-respondersTheratype

Substanzen

QuinolonesCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesIndolesDrug CombinationstezacaftorChloride Channel Agonistsdeutivacaftor, tezacaftor, vanzacaftor drug combinationSpiro Compounds

Autor:innen und Institutionen

  • UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Genova, Italy.
  • UOSD Centro Fibrosi Cistica, IRCCS Istituto Giannina Gaslini, Genova, Italy.
  • Department of Pediatrics, Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Gastroenterology and Transplantation, Cystic Fibrosis Regional Centre, Unit of Emerging and Immunosuppressed Infectious Diseases, Azienda Ospedaliero-Universitaria 'Ospedali Riuniti', Ancona, Italy.
  • UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Genova, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Italy.
  • UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Genova, Italy. Electronic address: nicolettapedemonte@gaslini.org.

Förderung

  • Ministero della Salute
  • Cystic Fibrosis Research Foundation

Zitieren

APA

Capurro, V., Pesce, E., Cresta, F., Pastorino, C., Mantero, A., Tomati, V., Daccò, V., Claut, L., Fabrizzi, B., Zara, F., Castellani, C., & Pedemonte, N. (2026). Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2026.05.015

Vancouver

Capurro V, Pesce E, Cresta F, Pastorino C, Mantero A, Tomati V, et al. Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment. Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2026.05.015

BibTeX
@article{Capurro2026,
  author = {Capurro, Valeria and Pesce, Emanuela and Cresta, Federico and Pastorino, Cristina and Mantero, Alice and Tomati, Valeria and Daccò, Valeria and Claut, Laura and Fabrizzi, Benedetta and Zara, Federico and Castellani, Carlo and Pedemonte, Nicoletta},
  title = {Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  doi = {10.1016/j.jcf.2026.05.015}
}
Kostenlos starten →